Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy
This article is the first in an 8-part series from the authors. The series, Waiting for new drugs for ...
Tag: Nigel Rawson
Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail
This article originally appeared in the Globe and Mail. By Nigel Rawson, March 17, 2023 Over the past six years, the ...
For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, January 24, 2023 Forty years ago ...
PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
‘Big Tobacco’ COVID-19 vaccine: What were the Liberals thinking? Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, April 22, 2022 After being late to ...
The Macdonald-Laurier Institute Welcomes Newest Senior Fellows, Nigel Rawson and John Adams
OTTAWA, ON (April 11, 2022): We are pleased to announce that Nigel Rawson and John Adams will be joining the ...
Timely access for patients to innovative medicines – A policy change overdue: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
Time to decide: Do we want foreign R&D or not? Richard C. Owens and Nigel Rawson in the Financial Post
This article originally appeared in the Financial Post. Below is an excerpt from the article, which can be read in ...
National drug plan process doesn’t add up: Nigel Rawson in the Hamilton Spectator
This article originally appeared in the Hamilton Spectator. By Nigel Rawson, February 23, 2022 Theatre of the Absurd features plays ...
Canadians will pay a heavy price as Ottawa cuts drug costs
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Top News
-
How post-colonialism is fuelling antisemitic protests across the West: Obaid Omer for Inside Policy
-
There’s no reason to believe CTV conspired against Pierre Poilievre. Here’s what the network actually did wrong: Peter Menzies in the Toronto Star
-
What Mark Carney should really tell the floundering federal government: Fen Osler Hampson and Tim Sargent in the Hub
-
Canada is disintegrating: Eric Kaufmann in the Telegraph
-
Canada’s NORAD modernization plan hinges on the North’s expertise and innovation: Lee Carson and Patrick Duxbury for Inside Policy
